Ali Zaidi

Mr. Ali Zaidi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
AZAli Zaidi
Ali Zaidi
PRPavithraa Ravi
Pavithraa Ravi
IBIngrid Bloise
Ingrid Bloise
SHSara Harsini
Sara Harsini
HSHeather Stuart
Heather Stuart
JLJonathan M Loree
Jonathan M Loree
Neuroendocrine tumors of unknown primary (CUP-NET) present a diagnostic challenge when conventional imaging fails to localize the primary tumor. This study aimed to evaluate the diagnostic value of concurrent [68Ga]Ga-DOTA-TOC and [18F]FDG PET/CT imaging in localizing primary tumors in patients with histologically confirmed CUP-NET. Thirty-four patients underwent both imaging modalities as part of a prospective imaging protocol after negative conventional imaging or [111In]In-octreotide scintigraphy. Primary tumor detection rates were assessed, and imaging characteristics compared between the two modalities. The overall localization rate was 58.9% (20/34). Of these, 90% (18/20) of primary tumors were identified solely by [68Ga]Ga-DOTA-TOC PET/CT, with the remaining two visualized by both modalities. [18F]FDG PET/CT did not independently localize any primary tumors. Identified primaries were limited to grade 1 (60%) or grade 2 (40%) tumors, predominantly in the small intestine (95%). Among localized cases, 45% (9/20) underwent surgical resection and 15% (3/20) became eligible for peptide receptor radionuclide therapy. [68Ga]Ga-DOTA-TOC PET/CT demonstrated superior detection of metastatic lesions compared to [18F]FDG PET/CT (97.1% vs. 70.6%, p = 0.006). No significant survival differences were observed between patients with localized versus non-localized primaries. These findings support the value of [68Ga]Ga-DOTA-TOC PET/CT for identifying primary tumors in CUP-NET. Further research is warranted to explore the role of [18F]FDG PET/CT in high-grade NETs.

10 February 2025 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
JVJoao Paulo Solar Vasconcelos
Joao Paulo Solar Vasconcelos
JRJose Eduardo Nunez Rodriguez
Jose Eduardo Nunez Rodriguez
AZAli Zaidi
Ali Zaidi
TKTharani Krishnan
Tharani Krishnan
HJHelia Jafari
Helia Jafari
JLJonathan M Loree
Jonathan M Loree
Advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) constitute a heterogeneous group of incurable cancers. Lenvatinib is an oral multiple kinase inhibitor that showed activity in grade 1/2 GEP-NENs in the phase II TALENT trial, but a confirmatory phase III study has yet to be conducted. To investigate the real-world use of lenvatinib in treating patients with advanced GEP-NENs, we retrospectively analyzed a cohort of adults with unresectable neuroendocrine neoplasms (NENs) from two academic centers in Canada who received palliative treatment with lenvatinib. Progression-free survival (PFS), overall survival (OS) and the treating clinician assessment of best therapeutic response were analyzed in the entire cohort and in the subgroup of patients with GEP-NENs that would have been eligible for the TALENT trial. Overall, 33 patients, with mostly G1/G2 (78.8%) metastatic NENs, received lenvatinib. The pancreas was the most common primary site (n = 16, 48.5%), followed by the small bowel (n = 12, 36.4%). The median number of prior lines of systemic therapy was 2 (range 1–5). The median initial, maximal and minimal doses (mg) were 12 (range 4–24), 12 (range 8–24) and 8 (range 4–24), respectively. The median PFS was 11.9 months (95% CI, 9.5–NA), and the median OS was 17.5 months (95% CI, 12.7–NA), with disease burden reduction seen in 21.9% (95% CI, 11.0–38.7) and 87.5% (95% CI, 71.9–95.3) of patients achieving disease control. The most frequent side effects reported were hypertension (60.6%), fatigue (39.4%), hypothyroidism (21.2%) and diarrhea (18.2%). This real-world cohort demonstrates encouraging evidence of lenvatinib activity in metastatic NENs, even when used at lower doses than previously studied in NENs.

1 October 2026 in JCO Precision Oncology
Verified
Journal Article
Closed access
AZAli Zaidi
Ali Zaidi
ETEmma Titmuss
Emma Titmuss
Renata D'Alpino PeixotoRenata D'Alpino Peixoto
Renata D'Alpino Peixoto
Sharlene GillSharlene Gill
Sharlene Gill
SGSharon Gorski
Sharon Gorski
GMGordon Taylor Moffat
Gordon Taylor Moffat
Purpose: The clinical utility of genomic profiling in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) remains incompletely defined, particularly for clinically relevant annotated alterations and prognostic stratification. We performed a multi-institutional analysis to characterize genomic alterations across GEP-NEN subtypes, generate prevalence estimates to inform precision oncology efforts, and evaluate associations with clinical actionability and survival. Methods: We performed a retrospective analysis of 1,691 GEP-NENs from the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange database. Tumors were classified into neuroendocrine tumors (NETs) or neuroendocrine carcinomas (NECs) and stratified by primary site. Genomic alterations, including single-nucleotide variants, insertions/deletions, copy number alterations, and structural variants, were analyzed using a panel-adjusted approach. Alterations were annotated for clinical relevance using multiple knowledge bases. Overall survival was evaluated in a subset (n = 502) with available data. Results: Genomic alterations were identified in 86.5% of patients. NETs were enriched for alterations in chromatin-remodeling genes ( MEN1, DAXX ) and mTOR pathway regulator TSC2 , whereas NECs were characterized by canonical drivers ( TP53, RB1, KRAS, APC , and BRAF ). Annotated alterations were identified in 34.1% of all patients, with higher rates in NECs compared with NETs (74.4% v 28.5%, P < .001). Notable annotated targets included BRAF V600E (2.2%; 14.8% of all colorectal NECs), KRAS -activating mutations (6.8%; 0.35% G12C), and NTRK fusions (0.2%). Annotation rates varied by primary site with the highest rates observed in colorectal, gastric, and esophageal NECs. In NETs, the presence of NEC-associated driver alterations was associated with worse overall survival (hazard ratio, 3.67 [95% CI, 2.49 to 5.42], P < .001). Conclusion: Genomic profiling reveals meaningful differences in biomarker prevalence and prognosis across GEP-NEN subtypes. These findings support integrating genomic profiling with histologic classification to refine risk stratification and inform biomarker-driven clinical trials.